Literature DB >> 842439

Studies on digitalis. XIII. A prospective study of 649 patients on maintenance treatment with digitoxin.

O Storstein, V Hansteen, L Hatle, L Hillestad, L Storstein.   

Abstract

In a prospective study of digitalis intoxication in 649 patients on maintenance treatment with digitoxin a low incidence of digitalis toxicity was found, namely, 5.8 per cent. This is mainly due to a more careful use to digitalis glycosides. It is especially important to reduce the dose of digitoxin in the liver and partly excreted metabolized in the liver and partly excreted through the kidneys as metabolities. Serum half-time of digitoxin is shortened in patients with impaired renal function. Patients with reduced renal function may be treated with digitoxin in the same doses as individuals with normal renal function. This is in contrast to patients treated with digoxin. Digitoxin should therefore be the cardiac glycoside of choice in treatment of patients with renal failure. Digitoxin is further rapidly eliminated in patients with reduced liver function in spite of its extensive hepatic metabolism. In this study extracardia symptoms were found equally often as cardiac signs of toxicity. Patients intoxicated usually had several symptoms and signs of toxicity at the same time. The specificity of commonly used symptoms and signs a digitalis intoxication is very low. In this study atrial tachycardia with block, which has been considered to be an important cardiotoxic arrhythmia, very seldom was found in digitalis intoxication. There is an overlap in digitalis serum concentration between toxic and nontoxic patients. The diagnosis of toxicity was made on clinical grounds. Most of the intoxicated patients had high serum concentrations, but some had concentrations in the normal or low range. Apart from being a guide to the diagnosis of digitalis intoxication, serum digitalis levels may further be a guide to underdigitalization of cardiac patients, especially patients in sinus rhythm.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 842439     DOI: 10.1016/s0002-8703(77)80405-5

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  10 in total

1.  Clinical pharmacokinetics of digitoxin.

Authors:  D Perrier; M Mayersohn; F I Marcus
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

2.  Effect of digoxin on the sensitivity to flickering light.

Authors:  C Guignard; V Van Toi; C W Burckhardt; J L Schelling
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

3.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

4.  The effect of age on digitoxin pharmacokinetics.

Authors:  M A Donovan; C M Castleden; J E Pohl; C A Kraft
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

5.  Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments.

Authors:  H R Ochs; T W Smith
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

6.  Acquired colour vision deficiency in patients receiving digoxin maintenance therapy.

Authors:  J G Lawrenson; C Kelly; A L Lawrenson; J Birch
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

7.  Magnesium status and digoxin toxicity.

Authors:  I S Young; E M Goh; U H McKillop; C F Stanford; D P Nicholls; E R Trimble
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

8.  Digoxin dosage in renal insufficiency: impracticality of basing it on the creatinine clearance, body weight and volume of distribution.

Authors:  F Keller; M Molzahn; R Ingerowski
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

9.  Effect of quinidine on the digoxin receptor in vitro.

Authors:  W J Ball; D Tse-Eng; E T Wallick; J P Bilezikian; A Schwartz; V P Butler
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

10.  The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients.

Authors:  Charalampos Dragonas; Jan T Wagner; Hans J Heppner; Thomas Bertsch; Wolfgang Muhlberg; Susanne Wicklein; Andreas Pahl; Christine Diewald; Iouri Bachmakov; Cornel C Sieber; Martin F Fromm
Journal:  Eur J Clin Pharmacol       Date:  2007-12-16       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.